BACKGROUND: The Directorate General of Drug Administration under the Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh,

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
Country Presentation Myanmar
Combating Counterfeit Drugs in China Chen Xu Ph.D. Director of Division of Drug Supervision and Inspection Department of Drug Market.
WHO Good Distribution Practices for Pharmaceutical Products
18th amendment to constitution of pakistan
World Health Organization
Medsafe – GMP update / release for supply / communicating quality issues Derek Fitzgerald Manager, Compliance Management 11 July 2013 RACI Pharmaceutical.
PRESENTED BY DR. JALAL MOKHALALATI, B.SC., M.SC., PH.D. QUALITY MEDICAL REGULATIONS SERVICES (QMRS) OTTAWA, ONTARIO, CANADA HEALTH.
Sanitation in the Food Industry Inspection Standards for the Food Industry.
“Reform of the Child Care System: Taking Stock and Accelerating Action” South East Europe 3 – 6 July 2007, Sofia.
February 2015, Italy EUROPEAN SOCIAL FUND 2007 – 2013 MINISTRY OF LABOUR AND SOCIAL POLICY ПОЛИТИКА HUMAN RESOURCES DEVELOPMENT OPERATIONAL PROGRAMME INVESTING.
 To provide for the health and safety of persons at work and for the health and safety of persons in connection with the use of plant and machinery;
Title, date Mr. Einar Magnússon Director, Department of Pharmaceutical Affairs Ministry for Health.
I&EHL: EU Pharmaceutical Law André den Exter
Drugs and Cosmetics Act, 1940 & Drugs and Cosmetics Rules 1945
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
Pharmaceutical System Strengthening : Bangladesh Perspective Aktari Mamtaz Joint Secretary Ministry of Health and Family welfare (MOHFW), Bangladesh.
What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.
National Medicine Policy
Traditional & Complementary Medicine in Malaysia [International Conclave on Traditional Medicine, New Delhi, INDIA Nov. 2006] Datuk Dr. M.S. Pillay.
Regulations Relating to Foodstuffs for Infants and Young Children (Foodstuffs, Cosmetics and Disinfectants Act, 1972) Briefing to the Portfolio Committee.
1 Confidential1 FOOD AND DRUG ADMINISTRATION-FDA Government Medical Colleges Attached hospitals Medical Education & Drugs Department Government of Maharashtra-
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
New Zealand Medicines and Medical Devices Safety Authority A business unit of the Ministry of Health.
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA. Presentation by: Dr. Joseph K. Yano B.Pharm (Nbi) L.L.B (Moi) Legal Officer Pharmacy and Poisons Board Ministry.
The South African perspective
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Staffing and Training.
046:127 Pharmaceutical Management for Underserved Populations  Paper on Current Controversy  Team Assignment: Observational Visits  National Drug Policy/Assessment.
Ornanong Mahakkapong Senior Researcher 18 May 2015
SFDA-2007 الهيئة العامة للغذاء والدواء Bioequivalence Studies of Generic Pharmaceutical Products Workshop-Day II Introduction and workshop Objectives By:
TRAINING FOR THE WEIGHTS AND MEASURES OFFICIAL COURSE CURRICULUM MODULE 1Introduction MODULE 2Laws & Regulations MODULE 3Enforcement Procedures MODULE.
And Pharmaceuticals Health Technology Technical Cooperation for Essential Drugs and Traditional Medicine Challenges of Medicine Regulation in Africa Global.
The Pharmaceutical Situational Analysis in Mongolia 1 Chimedtseren Munkhdelger 1 Sanjjav Tsetsegmaa 2, 1 Ministry of Health, 2 Pharmacy School, Health.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
STATE COMMITTEE for STANDARDIZATION of the REPUBLIC of BELARUS.
ACCESS TO MEDICINES - POLICY AND ISSUES
Licensing conditions of realisation economic activities of manufacture, wholesale and retail trade in medical products.
Consumer protection in Macedonia 10 march, Zagreb.
DISCOVERY HEALTH COMMENTS ON THE MEDICINES AND RELATED SUBSTANCES BILL August 2008.
1 CLUSTER : Pharmaceutical Policy & Planning Strategic Plans 2004/ /6 2006/7 31 May 2004.
Portfolio Committee for Health Medicines and Related Substances Amendment Bill (06/08/08) IMSA represents Research Based Pharmaceutical Companies.
Authorization and Inspection of Cyclotron Facilities The Authorization Process.
LAW RELATING TO MEDICAL PRACTICE 1. Allopathic system 2. Homeopathic system 3. Ayurvedic system 4. Unani Tib Available systems of medical practice are.
DRUG ACT 1976 SPECIFIC OBJECTIVES:
Draft Law of Kyrgyz Republic on Medicinal Products Syrdybaev Suyunbek, Head of expert group of ISWG of MoH KR 4 th Forum of МеТА Kyrgyz Republic Bishkek,
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
, International Regulatory and Health Authorities Inspections Maria Santaella Sr. Quality Director Janssen Ortho LLC Jansen Cilag Manufacturing LLC Gurabo,
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
GCP Guidelines for ASU drugs- Issues & Solutions
Veterinary Products Management and Quality Control System in Thailand : Veterinary Vaccine Tasanee Lorchaivej Workshop on the Veterinary Products.
Link between legal framework of VMP regulation and VICH GLs in Japan Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan.
INTRODUCTION A national drug policy is a document which covers all the areas and issues related to drugs. This document outlines all aspects of drugs.
The Law of the KR «On making amendments and changes to certain legislative acts of the KR» 4 th MeTA Forum in the Kyrgyz Republic Bishkek, December 8,
پنل نگاهی به جایگاه ایران در صادرات گیاهان دارویی، فرآورده های طبیعی و سنتی و بررسی مسائل و چالش های آن دکتر بی بی مهشید حایری زاده معاون اداره کل نظارت.
D & C - ACT.
Medicines Control Council (MCC) &
ROLES AND RESPONSIBILITIES OF VARIOUS LEVELS IN ESTABLISHING AND IMPLEMENTING THE ADDO PROGRAM August 2009.
PREPARATION FOR GMP INSPECTION
Industrial Pharmacy.
Dr Samvel Azatyan Technical Officer Regulatory Support
Prescription for Pharmaceutical Reform: Healing an Ailing System
National Medicines Policies
Medicines Control Council (MCC) &
Regulation in South-East Asia Joint Drugs Controller (India)
National Medicines Policies
A FRIENDLY REMINDER ON OTC DRUGS. DRUG REGULATIONS IN THE PHILIPPINES.
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA
WORKSHOP ON OPTIMAL PROCUREMENT OF AFFORDABLE AND QUALITY ASSURED LIFE-SAVING COMMODITIES FOR MATERNAL HEALTH KAMPALA, UGANDA - REGULATORY STATUS AND QUALITY.
GMP Legal Framework in Kyrgyzstan
Presentation transcript:

BACKGROUND: The Directorate General of Drug Administration under the Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh, is the Drug Regulatory Authority of the country. This Directorate supervises and implements all prevailing Drug Regulations in the country and regulates all activities related to import, procurement of raw and packing materials, production and import of finished drugs, export, sale, pricing, etc. of all kinds of medicine including those of Ayurvedic, Unani, Herbal and Homoeopathic systems. At present, there are 265 Allopathic, 201 Ayurvedic, 268 Unani, 25 Herbal and 79 Homeopathic drug manufacturing companies in the country. The Directorate General of Drug Administration monitors and regulates all the activities of these 838 companies. The chief of the Directorate, designated as the Director General, is also empowered by the Govt. to act as the Licensing Authority (LA) of drugs for the purpose of issuing licences to manufacture, store, sell, import and export drugs and medicines. medicines.

At present, there are 33 district offices of the Directorate in the country. All officers of the Directorate function as "Drug Inspector" pursuant to the Drug Laws and assist the Licensing Authority for properly discharging his responsibilities. Besides, a number of Committees, such as Drug Control Committee (DCC), Standing Committee for procurement and import of raw materials and finished drugs, Pricing Committee and a number of other relevant Committees, which comprise of experts, are there to advise the Licensing Authority and to recommend to him matters related to drugs and

Historical background Before An organization under the Central Govt of Pakistan under the Controller of drugs. After the war of liberation- An attached department of the Ministry of Health and Population Control. Since A separate Directorate directly under the Ministry of Health and Family Welfare, 17 January 2010 upgraded as the Directorate General of Drug Administration Responsibility The responsibilities of this organization are as follows : a. To ensure the quality, safety, efficacy and usefulness of all kinds of drugs and medicines including Homeopathic, Unani, Ayurvedic and Herbal drugs which are produced, imported and marketed in the country and also exported to overseas. b. To make essential drugs available and affordable to the common people of the country.

Legislation All the activities of DGDA are governed & guided by * The Drug Act 1940 * The Drug Rules 1945 and their amendments * The Drug Rules 1946 and their amendemnts * The Drug (Control) Ordinance 1982 and its amendments * The Drug (Control) Ordinance Amendment Act 2006 * National Drug Policy 2005

The Ordinance provides for the following legislative powers and responsibilities with respect to drugs and medicines: 1.Formation of a Committee of experts, called the DCC or Drug Control Committee, for consideration of registration of medicines and/or their cancellation. 2.Prohibition of manufacture and sale of drugs without the supervision of pharmacists. 3.Restriction on import of certain pharmaceuticals and finished drugs. 4.Review of under-licensing agreements. 5.Fixation of prices of essential drugs. 6.Control of advertisements and claims in respect of drugs. 7.Implementation of GMP in the manufacturing units as recommended by WHO. 8.Formation of Drug Courts for trying offenses related to drugs. 9.Formation of a National Drug Advisory Council for advising the Govt. on matters related to essential drugs. 10.Formation of an Appellate Authority. 11.Recognition of Traditional and Homeopathic medicines as drugs. 12.Imposition of penalty for : - manufacture and sale of adulterated, spurious and restricted drugs. - manufacture and sale of substandard drugs. - unauthorised import of drugs and raw materials. - sale of medicines at prices higher than the Maximum Retail Price(MRP) by the Licensing Authority. - theft of Drugs from Govt. hospitals and stores. - illegal advertisement of drugs and claims about their qualities and uses.

Major Function of DGDA 1. Evaluation of the proposals of new projects of all systems of medicines. 2. Issue and renewal of drug manufacturing licenses. 3. Issue and renewal of retail and whole sale drug licenses. 4. Registration and renewal of drug products. 5. Fixation of price and certification of price for drug products. 6. Inspection of pharmaceutical establishments 7. Approval of block list for the import of raw- and packaging materials. 8. Approval of indent for import of finished drugs. 9. Surveillance and pharmacovigillance activity 10.Prosecution of cases in the drug courts and other courts 11. Issue of export licenses, FSC (Free Sales Certificate), GMP (Good Manufacturing Practices) Certificate & CPP ( Certificate for Pharmaceutical Products.)